Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Cannabis
BRIGHT MINDS BIOSCIENCES INC.
Cannabis Intoxication
2 trials -
Cannabis
BRIGHT MINDS BIOSCIENCES INC.
Pain
2 trials -
Cannabis Cigarette
BRIGHT MINDS BIOSCIENCES INC.
Cannabis Use
1 trial -
Cannabis sativa Extract
BRIGHT MINDS BIOSCIENCES INC.
Cannabis Dependence
1 trial -
Carvedilol 25 mg tablets
Teva Pharma GmbH
Healthy
2 trials -
Casirivimab and Imdevimab Antibody Cocktail
Regeneron UK Limited
COVID-19
1 trial -
Cefzil® 500 mg tablets
Teva Pharma GmbH
Healthy
1 trial -
Cemiplimab
Regeneron UK Limited
Lung Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Advanced Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Advanced Malignancies
1 trial -
Cemiplimab
Regeneron UK Limited
Hormone Receptor-positive Breast Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Locally Advanced Head and Neck Squamous Cell Carcinoma
1 trial -
Cemiplimab
Regeneron UK Limited
Anaplastic Thyroid Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Epithelial Ovarian Cancer
1 trial -
Cemiplimab-Rwlc
Regeneron UK Limited
Merkel Cell Carcinoma
1 trial -
Ceralasertib, IMFINZI 50 mg/mL concentrate for solution for infusion, INFLIXIMAB, MYCOPHENOLATE MOFETIL, AZD4773, IMJUDO 20 mg/ml concentrate for solution for infusion.
AstraZeneca AB
• Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer
1 trial -
Characterization of Immune Response in Participants from a Posdinemab Study
Janssen-Cilag International N.V.
Early Alzheimer's disease
1 trial -
Cilostazol 100 mg tablets
Teva Pharma GmbH
Healthy
1 trial -
Cilostazol 50 mg Tablets
Teva Pharma GmbH
Healthy
1 trial -
Cisplatin
AstraZeneca
Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
1 trial -
Citarabina Hikma 2 g/20mL Soluzione Iniettabile, Idarubicin Hikma 1 mg/ml Injektionslösung, Cytarabine 100 mg/ml Solution for Injection or Infusion, Cytarabine 100 mg/ml Solution for Injection or Infusion, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, JNJ-75276617, JNJ-75276617 (G022), Venclyxto 100 mg film-coated tablets, Idarubicin, Venclyxto 100 mg film-coated tablets, JNJ-75276617, JNJ-75276617 (G023), Azacitidine, JNJ-75276617, Citarabina Hikma 500mg/5mL Soluzione I
Janssen-Cilag International N.V.
Acute Myeloid Leukemia
1 trial -
Clarithromycin ER 500 mg tablets
Teva Pharma GmbH
Healthy
2 trials -
Click-cleavable imaging in HER2-positive cancers (CleavHER trial).
Disc Medicine
HER2-positive tumors
1 trial -
Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.
Lacuna Pharma Pty Ltd
NASH
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources